Greenphire, ERT Tie Patient Reporting and Compensation
Greenphire announced a strategic partnership with ERT
Greenphire, a provider of payment technology for the clinical trial industry, announced a strategic partnership with ERT, a provider of high-quality patient safety and efficacy endpoint data collection. The partnership will integrate Greenphire's ClinCard System with ERT's electronic patient reported outcomes (ePRO) technology. The goal is to link patient reporting to compensation to enhance patient engagement and compliance.
This partnership will enable sponsors and CROs to offer real-time compensation to patients for compliance with study protocols by linking their ePRO activity to a ClinCard personal debit card. In addition to using Greenphire's system to compensate participants with stipends for site visits, clients can customize out-of-office reimbursement for patients' time and effort based on the specific requirements of each protocol.
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
